The future of GLP-1 RAs lies in their potential to address a wider array of metabolic disorders, supported by ongoing research and innovation (43)(47).GLP-1 receptor agonists, when integrated into comprehensive treatment plans, serve as tools in improving the lives of patients with T2DM and obesity
SoWell Calm is formulated specifically for GLP-1 users and contains magnesium glycinate, GABA, L-theanine, taurine, and myo-inositol ingredients that address the specific mechanisms by which GLP-1 medications disrupt sleep
GLP-1 directly activates anorexigenic POMC and CART neurons and indirectly inhibits, via GABAergic transmission, orexigenic NPY and AgRP neurons [39]
Because our bodies are constantly exposed to environmental stressors and free radicals, providing daily antioxidant support can help maintain a healthy balance
Biologics are driving much of this growth, expanding at a 15% annual rate, almost 3x faster than traditional pharma manufacturing